Search clinical trials for: Lu AA21004

Total 296 results

Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Peking Union Medical College Hospital

Recruiting

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
University of California, San Francisco
National Cancer Institute (NCI); Prostate Cancer Foundation

Active, not recruiting

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
H. Lundbeck A/S

Completed

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

Schizophrenia

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France; Advanced Accelerator Applications

Recruiting

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM)

Pancreatic Neuroendocrine Carcinoma

France
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
Gilead Sciences

Completed

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension (Darusentan)

Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Denmark, France, Germany, New Zealand
H. Lundbeck A/S

Terminated

Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

Major Depressive Disorder

Canada
Dana-Farber Cancer Institute
Novartis

Recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Grupo Espanol de Tumores Neuroendocrinos
MFAR; ITM Oncologics GmbH

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL)

Thymus Neoplasms | Neuroendocrine Tumors | Lung Neuroendocrine Neoplasm

Spain, Italy, France
Melanoma and Skin Cancer Trials Limited

Recruiting

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

Metastatic Merkel Cell Carcinoma

Australia
H. Lundbeck A/S

Completed

Safety and Efficacy of Zicronapine in Patients With Schizophrenia

Schizophrenia

Czech Republic, Estonia, Finland, France, Poland
OncoC4, Inc.
Prostate Cancer Clinical Trials Consortium

Recruiting

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (PRESERVE-006)

Metastatic Castration-resistant Prostate Cancer

United States
H. Lundbeck A/S

Completed

Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

Alzheimer Dementia (AD)

China
Novartis Pharmaceuticals

Recruiting

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Breast Cancer

France, Germany, Spain, Portugal
H. Lundbeck A/S

Completed

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

Healthy

United States
Georgetown University
Bristol-Myers Squibb; Advanced Accelerator Applications

Completed

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States
H. Lundbeck A/S

Completed

Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Efficacy of Lu 31-130 in Patients With Schizophrenia

Schizophrenia

Philippines, Hong Kong, Czech Republic, France, Indonesia, Poland, Spain, Thailand
University Hospital, Bordeaux
Advanced Accelerator Applications

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)

Neuroendocrine Tumor | Liver Metastases | Neuroendocrine Gastroenteropancreatic Tumour

France
University of Warmia and Mazury
Stowarzyszenie Pacjentów i Osób Wspierających Chorych na Guzy Neuroendokrynne

Unknown

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression (POLNETS_PRRT)

Neuroendocrine Tumors

Poland
H. Lundbeck A/S

Completed

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Major Depressive Disorder

Ukraine, Lithuania, France, Austria, Russian Federation, Australia, Belgium, Canada, Czech Republic, Finland, India, Korea, Republic of, Malaysia, Norway, Philippines, Serbia, Sweden
Jules Bordet Institute

Withdrawn

Randomized Phase III of PRRT Versus Interferon (CASTOR)

Gastro-intestinal Neuroendocrine Tumors

Belgium
University Hospital of Ferrara

Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) (FENET-2016)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy (PRRT)

Italy
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Gastro-enteropancreatic Neuroendocrine Tumor

Spain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
H. Lundbeck A/S

Completed

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (DayBreak)

Schizophrenia

Estonia, Mexico, Poland, Serbia, Ukraine, United States, Bulgaria, Canada, Czechia, Finland, Romania, Russian Federation, Slovakia, Spain
H. Lundbeck A/S

Completed

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Cytochrome P450 Interaction

United Kingdom, United States
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Schizophrenia | Bipolar I Disorder

United States
H. Lundbeck A/S

Terminated

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (Anew)

Treatment-resistant Schizophrenia

United States, Japan, Russian Federation, Bulgaria, United Kingdom
University Hospital, Basel, Switzerland
Swiss Cancer League

Recruiting

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (PROMENADE)

Meningioma

Switzerland
ITM Solucin GmbH
ABX CRO; PSI CRO

Active, not recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

Neuroendocrine Tumors

Germany, France, United States, United Kingdom, Australia, Italy, Belgium, Switzerland, Czechia, Spain, Austria, Netherlands, Poland, South Africa
Takeda

Completed

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Takeda

Completed

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

Depressive Disorder, Major
Takeda

Completed

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
H. Lundbeck A/S

Completed

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

Drug Reactions

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
H. Lundbeck A/S

Completed

A Trial Investigating Lu AF28996 in Healthy Adult Participants

Healthy Participants

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
ITM Solucin GmbH

Recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

Neuroendocrine Tumors

United States, United Kingdom, Australia, Netherlands, France, Italy, Spain, Germany, Sweden, India
H. Lundbeck A/S

Completed

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

Healthy

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma

United States

Search clinical trials for: Lu AA21004

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations